AMGN Stock Analysis — Amgen
Sector: Healthcare
AI Verdict
Amgen trades at 14.5x next year's earnings while analysts expect a huge 58.1% EPS jump — that's cheap for the growth you're getting, and its biologics moat makes the forecast more credible than most.
Competitive Moat
Amgen specializes in biologic drugs for chronic diseases, leveraging a deep pipeline and manufacturing expertise that make biosimilar competition difficult. Its established intellectual property portfolio and scale in biologics create high barriers to entry for rivals.
Summary
Amgen is notable right now for a forecasted 58.1% jump in earnings per share, far outpacing most large-cap pharma peers.
Where It Stands
Amgen delivered a 21.95% one-year return, trades at 14.5x forward earnings (below the healthcare median of 22x), and its RSI of 35.5 signals shares are just above oversold territory.
Key Metrics
- RSI: 35.5 — Near Oversold
- Trailing P/E: 22.9x
- Forward P/E: 14.5x
- PEG Ratio: 0.40
- Earnings Growth: +0.6%
- Revenue Growth: +0.1%
- Market Cap: $178.1B
- Dividend Yield: 0.03%
- 1-Year Return: 21.95%
- 52-Week High: $391.29
- 52-Week Low: $261.43
Analyst Consensus
21 Buy · 20 Hold · 3 Sell (44 analysts)
Bull Case
With analysts expecting 58.1% forward EPS growth and the stock trading at 14.5x forward earnings, the valuation is cheap for the growth on offer.
Bear Case
If Amgen's P/E reverts to the sector median of 22x from its current 14.5x forward, the stock could see a sharp rerating if growth disappoints or sentiment sours, especially with RSI barely above oversold at 35.5.
Catalyst to Watch
Watch for clinical trial readouts or regulatory approvals on late-stage pipeline drugs, as any setback could undermine the 58.1% EPS growth expectation.